Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Expands By 17.9%

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 6,180,000 shares, a growth of 17.9% from the September 30th total of 5,240,000 shares. Based on an average trading volume of 2,880,000 shares, the days-to-cover ratio is presently 2.1 days.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics in the third quarter worth approximately $133,000. Marshall Wace LLP purchased a new stake in Capricor Therapeutics during the 2nd quarter valued at $426,000. Renaissance Technologies LLC lifted its holdings in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the period. Main Street Financial Solutions LLC boosted its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Capricor Therapeutics in the second quarter worth $147,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 2.5 %

Shares of NASDAQ CAPR traded up $0.53 during midday trading on Tuesday, hitting $21.99. The stock had a trading volume of 1,313,940 shares, compared to its average volume of 1,150,871. The business’s 50 day moving average is $11.10 and its 200-day moving average is $7.14. Capricor Therapeutics has a 52 week low of $2.68 and a 52 week high of $23.40. The company has a market cap of $998.57 million, a P/E ratio of -23.65 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. As a group, analysts expect that Capricor Therapeutics will post -1.17 EPS for the current fiscal year.

Analyst Ratings Changes

CAPR has been the topic of several research reports. Maxim Group lifted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. Finally, Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.